Author:
Rivero-Yeverino Daniela,Payan Díaz Jonathan Higgins,López García Aida Inés,Papaqui Tapia José Sergio,Caballero López Chrystopherson Gengyny,Ríos López Juan Jesús,López Romero Carlos David,Sánchez Villalobos Johav Yael,Ortega-Jorga Rodríguez Elisa,Álvarez Rivera Armando,Villada Villada Erika
Abstract
Objectives: To evaluate the impact of cholecalciferol (D3) supplementation using clinical and paraclinical variables in patients with RA and vitamin D insufficiency and deficiency.
Methods: A randomized, double-blind, placebo-controlled study included patients from 5 to 40 years with a diagnosis of RA and vitamin D insufficiency and deficiency. They were supplemented for 8 weeks with 4000 or 5000 IU, depending on age. Total nasal symptoms score (TNSS) was measured monthly and 25(OH)D3 levels at baseline and at the end of the study.
Results: A total of 31 patients were included, with a mean age of 18.19 years. In the active group, there was a significant improvement in symptomatology with respect to the TNSS score and an increase in serum vitamin D levels (p < 0.01). There were no adverse reactions with cholecalciferol or placebo.
Conclusions: Supplementing patients with vitamin D3, at the evaluated dose, together with conventional treatment for allergic rhinitis results in symptoms and quality of life improvement in patients with this disease.
Keywords: Allergic rhinitis, Vitamin D, Placebo, Cholecalciferol, Supplementation.
Publisher
Colegio Mexicano de Inmunologia Clinica y Alergia, A. C.